AstraZeneca Results Presentation Deck

Early pipeline news flow (2/2) Next key milestone by project BioPharmaceuticals: Respiratory and Immunology 38 Project tozorakimab tozorakimab tozorakimab tozorakimab AZD1402 AZD4604 MEDI7352 MEDI7352 Target IL-33 IL-33 IL-33 IL-33 IL-4R alpha inhaled JAK NGF TNF NGF TNF Phase || || || || 11 1 || || Indication asthma COPD AD COVID-19 asthma asthma painful diabetic neuropathy osteoarthritic pain Next milestone Phase II data, H2 2022 Phase III start, 2022 Phase II data, H2 2022 Phase II data, H1 2022 Phase II data, H2 2022 Phase I data, 2023 Phase II data, 2023 Phase II data, 2023 Rare Disease Project ALXN1720 danicopan danicopan ALXN1820 ALXN2050 ALXN2050 ALXN2050 ALXN1850 Target 3rd-gen C5 Factor D Factor D anti-properdin Factor D Factor D Factor D next-gen asfotase alfa Phase I || I || || || | Indication gMG geographic atrophy PNH with EVH haematology PNH monotherapy gMG renal indications hypophosphatasia Next milestone Phase I data, H1 2022 Phase II data, 2023+ Phase III data, 2023 Phase I data, 2023 Phase II data, H1 2022 Phase II data, H1 2022 Phase II data, 2023+ Phase I data, H2 2022 B

View entire presentation